MS is inherently unpredictable. A person may appear physically stable during one evaluation but experience significant ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a ...

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis ...

The earliest symptoms of multiple sclerosis (MS) can come and go, which makes them easy to ignore — and makes diagnosing this common neurological disease complicated. That’s why it’s so important to ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

People who start taking medication soon after the first signs of multiple sclerosis (MS) may have a lower risk of disability later, according to a study published in the July 19, 2023, online issue of ...